Anti-CD19 CAR-T cell therapy is approved for patients up to 25 years of age based on the ELIANA study [44] and, more recently, for adult ALL based on the ZUMA-3 trial [45]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.